Ginkgo Biloba (Blackmores)
Ginkgo Biloba risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Blackmores, Swisse.
Ginkgo Biloba (brand names: Blackmores, Swisse) is classified as Low risk (1 risk points) by AllMeds. CAUTION: antiplatelet effect. Increases bleeding risk with warfarin, NSAIDs, aspirin.
Key Takeaways
- Risk level: Low (1 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | Unscheduled | Not PBS listed |
Risk Profile
CAUTION: antiplatelet effect. Increases bleeding risk with warfarin, NSAIDs, aspirin.
Regulatory and Compliance Guidance
When Ginkgo Biloba appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as Unscheduled under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- Ginkgo biloba — Cochrane review for cognitive impairment (2009)
Cochrane review finding inconsistent evidence for cognitive benefit. KEY: antiplatelet effect increases bleeding risk with warfarin, NSAIDs, aspirin.
Cochrane review — interaction profile more important than efficacy for AllMeds
Need to assess this medication across your caseload?
Run a full risk assessment including Ginkgo Biloba interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.